At a glance
- Originator University of Pennsylvania
- Developer Neurokappa Therapeutics
- Class Behavioural disorder therapies; Mood stabilisers; Neuropsychotherapeutics; Small molecules; Vascular disorder therapies
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cerebral vasospasm
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Cerebral-vasospasm in USA
- 26 Aug 2016 Chemical structure information added